|
A new PREMIER tool
April 2013
EDIT CONNECT
SHARING OPTIONS:
PALO ALTO, Calif.—Bioinformatics
company PREMIER Biosoft has
beefed up its mass spectrometry
product portfolio with the acquisition of
ProteoIQ, a comprehensive tool for comparative and quantitative proteomics,
from NuSep, a firm in Australia.
NuSep is a 30-year-old, publicly listed life-science company
that sells products into the global bioseparations market. Its biological
separation
techniques are based on its PrIME technology, which the company
claims has produced a number of world firsts, including the world's first IVF
sperm
separation instrument. NuSep's research team has developed an extensive
portfolio of patented products. The company currently manufactures, distributes
and sells 55 products to customers in the United States, Europe, Asia and
Australia.
In the
somewhat opaque world of bioinformatics, PREMIER has
significant credentials to boast of, according to company CEO Arun Apte, who
notes that the
company now offers a broad spectrum of products for mass
spectrometry-based 'omics and imaging studies to the research community.
"We have been in the bioinformatics market for close to two
decades," Apte notes. "Our very first product,
Primer Premier, was designed as
a primer design tool for standard PCR. It was an instant success. As
innovations happened, especially in the genomics
area, we subsequently
developed tools for cloning, qPCR and microarrays. Beacon Designer and
AlleleID, our products for qPCR, have been installed in
hundreds of labs around
the globe and are the only products on the market that support almost all the
popular qPCR chemistries. Array Designer is the
only oligo design tool for
microarrays that supports gene expression to splice variant to tiling to
resequencing arrays. We then forayed into mass
spectrometry and authored
products for glycomics and lipidomics, the new 'omics on the market. We built
partnerships with large mass spec companies to
place our products in the hands
of the users. Last year, we released MALDIVision, an MS imaging solution, as
well. It is the only tool on the market to
support 10GB MALDI imaging data."
Now, with the NuSep acquisition, PREMIER has entered the
attractive proteomics market.
"For the rapidly growing proteomics market, ProteoIQ is a
strategic
fit to PREMIER Biosoft's existing mass spec product offering, and
helps consolidate our position as a leader for providing informatics tools for
mass
spectrometry," says Apte. "Before the NuSep acquisition, a major product
that was missing from our mass spec portfolio was a proteomics tool. We zeroed
in on ProteoIQ by looking at the comprehensive functionality it offered. The tool
is capable of analyzing hundreds of LC-MS and LC-MS/MS runs that
contain
thousands of MS/MS spectra to validate, quantitate, annotate and compare
peptides and proteins across samples."
ProteoIQ is a software tool for proteomic data analysis that
streamlines the process of statistical validation, protein
quantification and
comparative proteomics on one platform. It supports validation of the proteins
identified by other database search tools such as
Mascot, SEQUEST or X!Tandem.
ProteoIQ incorporates the False Discovery Rate and Protein Probability
approaches for statistical validation of identified
proteins. It performs
quantitative analysis via spectral counting, precursor intensity, iTRACQ, TMT,
SILAC and iCAT workflows. Users can quickly
perform differential analysis of
results across biological samples thereby facilitating identification of
putative biomarkers. ProteoIQ calculates
global False Discovery Rate to
calculate an error rate for peptide identifications by searching Peptide MS/MS
spectra against a decoy database and
comparing the results with the normal
database search results. FDR defines an error rate for all results even though
it does not pinpoint the
identifications that are false. FDR is the most robust
approach for small data sets, Apte claims. Code: E041313 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|